参考资料: https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-berubicin-for-treatment-of-recurrent-glioblastoma-multiforme haoeyou.com/zhongliu_aizheng/jiaozhimuxib/20210708/6450.html
由于berubicin具有延长多形性胶质母细胞瘤患者总生存期的潜力，FDA授予berubicin治疗该复发性疾病的快速通道指定。据CNS Pharmaceuticals AG公司介绍，FDA已经授予berubicin用于治疗复发后的多形性胶质母细胞瘤（GBM）的快速通道指定。最近启动的一项2期研究（NCT04762069），评估了berubicin与洛莫司汀相比，治疗复发性GB...
CTNI-68. UPDATES ON A POTENTIALLY PIVOTAL TRIAL CNS-201: A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN VS. LOMUSTINE AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM)doi:10.1093/neuonc/noae165.0435Berubicin, derived from doxorubicin (Dox), appears to cross the BBB and has shown ...
has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable. With the completion of manufacturing at BSP and at its U.S. manufacturer, Phar...
参考资料: https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-berubicin-for-treatment-of-recurrent-glioblastoma-multiforme haoeyou.com/zhongliu_aizheng/jiaozhimuxib/20210708/6450.html
Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy.doi:10.1200/JCO.2022.40.16_suppl.TPS2083...
A pivotal trial for patients with recurrent glioblastoma (GBM) after first-line therapy has finished enrollment with 252 patients in the US and Europe with evidence of efficacy and no impact on cardiac function. METHODS. CNS Pharmaceuticals plans to evaluate Berubicin in patients with Primary CNS...